logo
This deadly prehistoric wasp captured prey with 'Venus flytrap' abs

This deadly prehistoric wasp captured prey with 'Venus flytrap' abs

In Greek mythology, the sea monster Charybdis swallowed and regurgitated large volumes of water, creating whirlpools powerful enough to drag passing ships to their doom. Ninety-nine million years earlier, in the mid-Cretaceous, the wasp Sirenobethylus charybdis deployed a similar deadly trap that earned it a scientific name inspired by the mythological monster.
A Venus flytrap-like structure on the wasp's abdomen held captives in place as the wasp deposited its eggs into its victim, forcing it to incubate its offspring. That's the finding of a new paper published in the journal BMC Biology that examined dozens of wasps entrapped in amber.
'This discovery reveals that ancient insects had already developed sophisticated prey capture strategies,' says Wu Qiong, the lead author and a doctoral student from the College of Life Sciences at Capital Normal University, 'It's reshaping our understanding of parasitic wasp evolution.'
The amber containing the specimen Sirenobethylus charybdis is no larger than a dime. In 2015, a Chinese fossil collector purchased these fossils from Myanmar's Kachin state and donated them to Capital Normal University of China.
To the naked eye, Sirenobethylus charybdis looks like a modern wasp with a wider-than-average abdomen.
'At first, we attributed this to deformation during preservation, especially since such deformation and distortion is common during fossilization,' says Wu.
But under closer inspection—through microscope and CT scans—a remarkable structure was revealed.
The abdominal tip of the wasp featured three flaps arranged in a configuration similar to a Venus flytrap. On multiple fossils, the lower flap opened at slightly different angles, suggesting it can move and grab onto things. Just like a Venus flytrap, the underside of the lower flap is also lined with long, flexible hairs that sense movement. A closer examination of the fossil revealed a feature that allowed the wasp to grasp prey, similar to a Venus flytrap.
When an unsuspecting insect triggered these hairs, it may have activated the swift closure of the abdominal flaps, allowing the wasp to secure the host.
Scientists don't think the wasp killed its victims right away but instead used it as a living incubator for its offspring.
Numerous stiff, hair-like structures on the upper side of the lower flap, along with the relatively pliable middle flap, would gently but firmly secure the host until the wasp finished laying its eggs. Only then would the wasp release its captive.
'The 'Venus flytrap' structure exhibited by the abdomen of Sirenobethylus charybdis is unprecedented in the entire history of Mesozoic insect research,' says Wu, 'nor has anything similar been documented in living insects.'
Chenyang Cai, who was not involved in the study, is a paleoentomologist at Nanjing Institute of Geology and Palaeontology at the Chinese Academy of Sciences. He praised the fossil wasp as a 'unique' discovery. He explained that Sirenobethylus charybdis is 'very different from today's wasps or other insects' and its existence 'highlights the diversity of insects in the mid-Cretaceous period, revealing forms we had never imagined'.
Scientists don't know which insects Sirenobethylus charybdis used to host its eggs. Given the small size of its trapping structure, these hosts were possibly tiny, agile insects such as springtails or small flies.
By studying similar species living today, the team pieced together other theories about this prehistoric wasp.
As a distant relative of Sirenobethylus charybdis, the present-day pincer wasp has also evolved the ability to trap its host—temporarily restraining it, laying eggs, and then releasing it.
Female pincer wasps have front legs modified with a pinching apparatus, allowing them to firmly grasp hosts when they lay eggs. These wingless hunters, with large eyes and slender legs, are well adapted for moving swiftly and capturing other insects.
In contrast, Sirenobethylus charybdis appears to be more cumbersome. They have smaller eyes and shorter legs, which suggest they were slower than pincer wasps.
The grasping structure located at the rear of their body also makes it difficult to capture hosts in motion. Based on these characteristics, researchers think it was a sit-and-wait predator—likely remaining stationary and ambushing hosts that wandered too close.
Mid-Cretaceous amber fossils like this one, noted Cai, reveal insects of that age were 'incredibly diverse—perhaps even more specialized in some cases than what we see today.'
Such findings, he emphasizes, are 'a crucial reminder that studying only living species will never give us the complete story of evolution.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Moon over Musk
Moon over Musk

Politico

time41 minutes ago

  • Politico

Moon over Musk

Presented by The Spotlight The alliance between Donald Trump and Elon Musk — to borrow a phrase from the space community — has undergone a rapid unscheduled disassembly. Yet amid all the fireworks Thursday from the duo's public meltdown, one area of the space world seems to have a brighter future: the moon mission. Context: Musk, the SpaceX founder and well-known Mars enthusiast, has argued against returning astronauts to the lunar surface. But the stunning forced exit of the billionaire's hand-picked nominee for the top NASA job and Musk's massive rupture with the president has handed moon backers in Congress and industry an opening — and they're seizing it. What's happening, Part I: A ton of major space companies — just not SpaceX — are launching an ad campaign going big on the moon, according to two industry officials granted anonymity to discuss the effort. The move is the first sign of real pushback against the behemoth space company and its founder, who only days ago seemed to lock down government contracts every time he blinked. A television ad funded by the companies, who do not go by an umbrella name, will appear on television in the coming days with a pitch clearly aimed at Trump. A narrator, underlaid by dramatic images of America's Apollo missions, implores voters to call senators in support of the moon mission and 'keep America first in space.' A separate letter addressed to the Senate Commerce Committee and obtained by POLITICO backs investments in the moon, and is signed by a lengthy slate of prominent space companies — but not (you guessed it) SpaceX. What's happening, Part II: The Senate Commerce Committee on Thursday evening unveiled a new reconciliation bill that would channel $10 billion to NASA, much of it for the space agency's effort to return to the moon through the Artemis program. The White House's NASA budget had proposed major cuts to Artemis, including slashing a planned lunar space station and moon missions. 'Anybody who's following space will have noticed how deeply committed [the committee is] to getting back to the moon, particularly before the Chinese get there,' said a committee aide, who was granted anonymity to discuss the bill. SpaceX'd Out: All of this is happening amid Musk's very public fall from grace. Trump, during the social media showdown with his former confidante, threatened to cancel Musk's contracts with the government. The SpaceX founder responded by saying he would end the Dragon spacecraft contract, which is the U.S.'s only reliable way of accessing the International Space Station. (But he also suggested late Thursday night that he might not actually do so.) And of course, Trump last week abruptly pulled the NASA administrator nomination for Musk ally Jared Isaacman, just days ahead of his likely confirmation by the Senate. Isaacman, speaking on a podcast this week, linked his ouster to Musk's provocative departure from the White House. 'I don't think the timing was much of a coincidence,' he said. What next: This all means Congress may now have a stronger hand in negotiations with the White House over the NASA budget, which was written before Musk's break from Trump and heavily favors Mars. The administration's budget proposes major cuts to spending for the moon in favor of nearly $1 billion for landing an astronaut on Mars. SpaceX, thanks to provisions in the bill, was likely to snag a lucrative contract to build the landing system for any red planet mission. That seems much less feasible now. Senators from states with large NASA centers — think Alabama and Louisiana — are particularly keen to latch onto moon funding. Trump has voiced support for a Mars mission, meaning the idea may not have completely faded. But with Musk's implosion and the latest moon push, a return to the lunar surface is on firmer ground than it was just a week ago. WELCOME TO POLITICO PRO SPACE. It's our inaugural edition and a telling time to start. We've seen deep slashes to NASA's budget, the space agency's nominee pulled, and a feud explode between the world's biggest space contractor and the president. We can't wait for next week. Email me at sskove@ with tips, pitches and feedback, and find me on X at @samuelskove. We're offering this newsletter for free over the next few weeks. After that, it will be available only to POLITICO Pro subscribers. Read all about what we're doing here. Galactic Government MAKE A DEAL: Florida Rep. Mike Haridopolos, who chairs the House's subcommittee on space and aeronautics, told me Wednesday that he was against the White House's massive NASA cuts — making him one of the first Republicans to publicly voice opposition. 'Will a 26 percent cut to NASA hold? Absolutely not,' he said. 'We're going to be talking with the president and his team, with OMB about the paramount importance of space.' China: Haridopolos emphasized competition with China as a driving reason not to slash the space agency's funding. The proposed cancellation of Gateway — a lunar space station partnership with the European Space Agency — opens the way for Chinese influence, he said. Sen. Ted Cruz, the Texas Republican who leads the committee that oversees NASA, underscored a remarkably similar message during Isaacman's confirmation hearing. The Florida lawmaker said he was optimistic that the cuts wouldn't come to fruition. Trump 'believes in the space program,' he said. 'He knows that we want there's no second place to space.' TICKET TO RIDE: Sens. John Cornyn, Ben Ray Luján, Rick Scott, and Mark Kelly introduced a bill Thursday that would streamline licensing processes for commercial space companies, opening the way to a boom in rocket launches. The bill, dubbed the Launch Act, would allow the Federal Aviation Administration to eliminate overly bureaucratic steps in the application process. The law would also create a streamlined process for licensing commercial satellites used to observe the Earth. And it would move the Office of Space Commerce from the National Oceanic and Atmospheric Administration and place it directly under the Transportation secretary, a move that would elevate the office's access to key decision makers. Why it matters: Companies such as SpaceX have long complained about the slow pace of launch licensing. Streamlining the process could lead to a significant uptick in an already booming schedule. Companies launched 145 U.S. rockets in 2024, up from 109 the previous year. Military SPACE COMMAND: Lawmakers pressed Air Force Secretary Troy Meink on Thursday to keep U.S. Space Command in Colorado as the Trump administration weighs moving the headquarters to Alabama. The Defense Department established the command in 2019 and temporarily placed it in Colorado while the Air Force evaluated permanent sites. Trump chose Alabama as the permanent headquarters but former President Joe Biden reversed that decision and selected Colorado. What he said: Meink, in a House Armed Services Committee hearing, conceded that Space Command would see civilian employees quit if the HQ moved from Colorado to Alabama. 'It would be very important that we manage that move over a period of time, if that occurs,' the Air Force chief said. Rep. Jeff Crank (R-Colo.) called for the Pentagon to resume headquarters construction at Peterson Space Force Base in Colorado Springs, calling it the 'most effective' home for Space Command. Context: Officials have paused construction because of a legal requirement to hold off until the Pentagon inspector general and the Government Accountability Office released their reports on the Biden administration's 2023 basing decision. Those reports are out, but Meink said the Air Force is still reviewing the GAO's findings. The Reading Room — Senate Commerce reconciliation bill proposes new space launch fee: POLITICO — Space Force awards BAE $1.2B for missile warning sats in MEO: Breaking Defense — Impulse Space Raises $300M Series C: Payload — Space Force shifts upfront range upgrade costs to commercial firms: Defense News — Some parts of Trump's proposed budget for NASA are literally draconian: Ars Technica Event Horizon TUESDAY: Axiom-4 launches private astronauts to the International Space Station. The Hudson Institute holds a discussio n on defending in outer space with Rep. Jeff Crank. Rep. George Whitesides speaks with SpaceNews on space issues. FRIDAY: The FAA ends public comments on a launch licensing-related issue. Photo of the Week

ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS CLARUS 700 Receives NMPA Approval in China

Yahoo

time12 hours ago

  • Yahoo

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS CLARUS 700 Receives NMPA Approval in China

Yahoo

time12 hours ago

  • Yahoo

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store